Clinical Trial Update: A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating efgartigimod for adult primary immune thrombocytopenia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Efgartigimod (efgartigimod)

Snippet

Sponsor: argenx | Conditions: Primary Immune Thrombocytopenia (ITP) | Phase 3 | Status: WITHDRAWN